Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | DRD4 | P21917 | 6/20 | 0.55 |
| ▸ | DRD3 | P35462 | 6/20 | 0.55 |
| ▸ | DRD1 | P21728 | 2/20 | 0.55 |
| ▸ | DRD5 | P21918 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527765 | 0.84 | DRD2 (0.38) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL22691798 | 0.78 | DRD2 (0.37) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL11171775 | 0.75 | DRD2 (0.52) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL96585 | 0.73 | MAOA (0.39) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL13672485 | 0.73 | DRD2 (0.50) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL10712171 | 0.73 | CCNB2 (0.47) | RAB9ANPSR1CCNB2CDK1CCNB1 | |
| SCHEMBL10711508 | 0.73 | TDP2 (0.43) | RAB9ANPSR1CCNB2CDK1CCNB1 | |
| SCHEMBL3484935 | 0.72 | AHR (0.50) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL10923362 | 0.71 | DRD2 (1.00) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL7091144 | 0.71 | DRD2 (0.47) | DRD2DRD4DRD3DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8796307-B2 | Beta2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-8658673-B2 | BETA2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8436017-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8283362-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2012-10-09 | — | — | US | disclosed |
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20120077838-A1 | Beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD (GB) | 2012-03-29 | — | — | US | disclosed |
| US-8067437-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2011-11-29 | — | — | US | disclosed |
| US-20110034509-A1 | Beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD | 2011-02-10 | — | — | US | disclosed |
| US-7820694-B2 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100029705-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | CUENOUD BERNARD | 2010-02-04 | — | — | US | disclosed |
| US-7622483-B2 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | DRD2 23/4885DRD4 53/4885DRD3 41/4885 |
| US-20110034509-A1 | Beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | DRD2 240/4885DRD4 675/4885DRD3 286/4885 |
| US-20120077838-A1 | Beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | DRD2 240/4885DRD4 675/4885DRD3 286/4885 |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | DRD2 248/4885DRD4 622/4885DRD3 325/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | DRD2 18/4885DRD4 76/4885DRD3 46/4885 |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | DRD2 121/4885DRD4 379/4885DRD3 195/4885 |
| US-20100029705-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | DRD2 12/4885DRD4 30/4885DRD3 11/4885 |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRB3 | DRD2 268/4885DRD4 621/4885DRD3 297/4885 |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | DRD2 240/4885DRD4 675/4885DRD3 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.